Basis of preparation and statement of compliance - Significant Investments In Subsidiaries (Details) € in Thousands |
6 Months Ended | 12 Months Ended | |||
---|---|---|---|---|---|
Jun. 30, 2025
EUR (€)
$ / €
entity
|
Jun. 30, 2024
$ / €
|
Dec. 31, 2024
$ / €
|
May 09, 2025
$ / €
|
May 07, 2025
$ / €
|
|
General principles and statement of compliance | |||||
Number of entities being consolidated | entity | 2 | ||||
Exchange rate at the end of period | 1.172 | 1.0705 | 1.0389 | ||
Hepalys Pharma, Inc | |||||
General principles and statement of compliance | |||||
Proportion of ownership interest | 15.00% | 15.00% | 15.00% | ||
Licensing and collaboration agreement with CTTQ | |||||
General principles and statement of compliance | |||||
Exchange rate at the end of period | 1.125 | 1.125 | 1.172 | ||
Inventiva Inc. | |||||
General principles and statement of compliance | |||||
Percent of ownership interest | 100.00% | ||||
Non-controlling interest | € | € 0 |